TRYP Therapeutics Announces results of First Patient Dosed in its Phase II Clinical Trial for the Treatment of Binge Eating Disorder
Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder San Diego, California — (June 9, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )